CIK 0001314102 · Non-accelerated filer<br>Smaller reporting company
EyePoint, Inc.
Sign in to watch- Ticker
- EYPT
- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 262774444
- Phone
- 617-926-5000
- Business address
- 480 PLEASANT STREET, SUITE C400, WATERTOWN, MA, 02472
- Former names
- EyePoint Pharmaceuticals, Inc., pSivida Corp., pSivida LTD
- Open-market buys, last 90 days
- $52,258
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$52,258. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-26 | Paggiarino Dario A. Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,609 | 1,026 | ||
| 2024-01-26 | Jones David Scott SVP & Chief Commercial Officer | Option exercise 10b5-1 | +9,604 | $12.90 | $124K | 47,566 |
| 2024-01-26 | Jones David Scott SVP & Chief Commercial Officer | Option exercise 10b5-1 | +16,413 | $3.26 | $54K | 63,979 |
| 2024-01-26 | Jones David Scott SVP & Chief Commercial Officer | Sale 10b5-1 | −16,413 | $25.45 | $418K | 47,566 |
| 2024-01-26 | Jones David Scott SVP & Chief Commercial Officer | Sale 10b5-1 | −9,604 | $25.27 | $243K | 37,962 |
| 2024-01-26 | Jones David Scott SVP & Chief Commercial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,604 | 8,721 | ||
| 2024-01-26 | Jones David Scott SVP & Chief Commercial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −16,413 | 68,742 | ||
| 2024-01-25 | Paggiarino Dario A. Chief Medical Officer | Option exercise 10b5-1 | +300 | $13.13 | $4K | 36,805 |
| 2024-01-25 | Paggiarino Dario A. Chief Medical Officer | Option exercise 10b5-1 | +300 | $12.90 | $4K | 37,105 |
| 2024-01-25 | Paggiarino Dario A. Chief Medical Officer | Sale 10b5-1 | −300 | $25.00 | $8K | 36,805 |
| 2024-01-25 | Paggiarino Dario A. Chief Medical Officer | Sale 10b5-1 | −300 | $25.00 | $8K | 36,505 |
| 2024-01-25 | Paggiarino Dario A. Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −300 | 51,304 | ||
| 2024-01-25 | Paggiarino Dario A. Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −300 | 16,635 | ||
| 2024-01-25 | Jones David Scott SVP & Chief Commercial Officer | Option exercise 10b5-1 | +300 | $12.90 | $4K | 38,262 |
| 2024-01-25 | Jones David Scott SVP & Chief Commercial Officer | Option exercise 10b5-1 | +300 | $3.26 | $978 | 38,562 |
| 2024-01-25 | Jones David Scott SVP & Chief Commercial Officer | Sale 10b5-1 | −300 | $25.00 | $8K | 38,262 |
| 2024-01-25 | Jones David Scott SVP & Chief Commercial Officer | Sale 10b5-1 | −300 | $25.00 | $8K | 37,962 |
| 2024-01-25 | Jones David Scott SVP & Chief Commercial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −300 | 18,325 | ||
| 2024-01-25 | Jones David Scott SVP & Chief Commercial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −300 | 85,155 | ||
| 2024-01-24 | Jones David Scott SVP & Chief Commercial Officer | Option exercise 10b5-1 | +5,600 | $12.90 | $72K | 43,562 |
Page 14 of 18 · 352 trades